期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 66, 期 2, 页码 235-239出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkq448
关键词
antituberculosis; anticoagulants; pulmonary hypertension; chemotherapy; HIV
资金
- Abbott Laboratories
With HIV-infected patients living longer and recommendations to initiate antiretrovirals (ARVs) being made earlier, the likelihood for potential drug-drug interactions between ARVs and concurrent medications used to manage co-morbid conditions will increase. In order to maximize the clinical benefit and minimize potential toxicity of ARVs and co-administered medications, it is important for clinicians to recognize significant drug-drug interactions. This article highlights clinically significant drug-drug interactions with antituberculosis agents, antimalarials, anticoagulants, chemotherapeutic agents and pulmonary antihypertensive agents when they are co-administered with newer ARVs (e.g. darunavir, raltegravir, maraviroc and etravirine).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据